更新于：2024-12-15
Zastaprazan citrate
更新于：2024-12-15
概要
基本信息
药物类型 小分子化药 |
别名 JP 1366、JP-1366、JPI-547 + [2] |
作用机制 ATPase抑制剂(ATP酶抑制剂)、钾离子竞争性酸阻滞剂(钾离子竞争性酸阻滞剂) |
非在研适应症 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 韩国 (2024-04-24), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C28H34N4O8 |
InChIKeyLYCCRSPDKSGPRQ-UHFFFAOYSA-N |
CAS号2936619-43-9 |
关联
11
项与 Zastaprazan citrate 相关的临床试验A Multicenter, Parallel, Double-blind, Randomized, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 Treatment in the Prevention of (NSAIDs)-Induced Peptic Ulcers
一项在中国健康受试者中评价口服不同剂量JP-1366片单次和多次给药的药代动力学I期临床研究
A Randomized, Open-label, Crossover Phase 1 Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers
100 项与 Zastaprazan citrate 相关的临床结果
登录后查看更多信息
100 项与 Zastaprazan citrate 相关的转化医学
登录后查看更多信息
100 项与 Zastaprazan citrate 相关的专利（医药）
登录后查看更多信息
7
项与 Zastaprazan citrate 相关的文献（医药）2024-10-01DRUGS
Correction: Zastaprazan: First Approval
作者: Blair, Hannah A
2024-07-01DRUGS
Zastaprazan: First Approval
Review
作者: Blair, Hannah A
Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker being developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, for the treatment of acid-related diseases. Zastaprazan binds directly to proton pumps in a competitive manner to reduce gastric acid secretion, allowing for a quick onset of action. On 24 April 2024, zastaprazan received approval in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). Zastaprazan is also undergoing phase III development for the treatment of gastric ulcer and for the prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer. This article summarizes the milestones in the development of zastaprazan leading to this first approval for erosive GERD.
2023-06-01Pharmacology research & perspectives
JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases.
Article
作者: Cha, Hyunju ; Kim, Jong Yup ; Ku, Jin Mo ; Kim, John ; Cho, Jin Hee ; Kim, Ji Yoon ; Cheon, Banyoon ; Kim, Kangjeon
The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long-term or lifetime administration; thus, the development of more effective therapeutic agents is needed. Herein, a more effective treatment for GERD was tested. We investigated whether JP-1366 affected gastric H+/K+-ATPase activity and used the Na+/K+-ATPase assay to confirm the selectivity of H+/K+-ATPase inhibition. To clarify the mechanism of enzyme inhibition, JP-1366 and TAK-438 were analyzed by Lineweaver-Burk. Also, we investigated the effects of JP-1366 in various models involving reflux esophagitis. We found that JP-1366 mediates strong, selective, and dose-dependent inhibition of H+/K+-ATPase. We found that JP-1366 significantly suppressed gastric acid secretion in histamine-treated pylorus-ligated rats in a dose-dependent manner. Additionally, we confirmed that JP-1366 inhibited histamine-stimulated gastric acid secretion in the HPD model. JP-1366 exhibited a more than 2-fold higher inhibitory effect on esophageal injury than TAK-438 in GERD lesions and had a more potent inhibitory effect in indomethacin- or aspirin-induced gastric ulcer rat models than TAK-438. Additionally, JP-1366 inhibited gastric ulcers. These results support the possibility that JP-1366 is a good candidate drug for treating acid-related diseases.
100 项与 Zastaprazan citrate 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性胃食管反流病 | 韩国 | 2024-04-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 反流性食管炎 | 临床3期 | 中国 | 2024-11-22 | |
| 反流性食管炎 | 临床3期 | 中国 | 2024-11-22 | |
| 胃溃疡 | 临床3期 | 韩国 | 2022-09-19 | |
| 糜烂性食管炎 | 临床3期 | 韩国 | 2022-01-17 | |
| 幽门螺杆菌相关性胃炎 | 临床1期 | 韩国 | 2020-11-18 | |
| 溃疡 | 临床1期 | 韩国 | 2017-12-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | zastaprazan 20 mg | 鹽鏇築齋壓夢選鏇淵襯(遞觸顧製鏇範積齋築鹽) = 淵觸簾鹽淵廠齋鬱簾鏇 蓋壓淵遞壓鏇糧繭糧網 (廠網廠廠鑰觸繭鹹鑰餘 ) 更多 | 非劣 | 2024-05-29 | ||
埃索美拉唑 40 mg | 鹽鏇築齋壓夢選鏇淵襯(遞觸顧製鏇範積齋築鹽) = 鏇築積衊齋網選夢衊鑰 蓋壓淵遞壓鏇糧繭糧網 (廠網廠廠鑰觸繭鹹鑰餘 ) 更多 | ||||||
Pubmed 人工标引  | 临床阶段不明 | - | Zastaprazan 20mg | 艱顧襯鏇憲簾選遞餘醖(鏇壓簾醖夢衊醖壓選夢) = 餘齋繭艱範齋蓋廠願觸 繭餘糧廠壓鹹顧繭積構 (構製鏇蓋觸衊鏇鹹網顧 ) | 积极 | 2023-02-02 | |
Zastaprazan 40mg | 艱顧襯鏇憲簾選遞餘醖(鏇壓簾醖夢衊醖壓選夢) = 憲窪淵鏇構顧遞鑰鹽鹽 繭餘糧廠壓鹹顧繭積構 (構製鏇蓋觸衊鏇鹹網顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用